• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Blog » KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

General Psychiatry

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

October 18, 2024
Jason Mallo, DO and Greg Malzberg, MD
Alpha2Thumb.png


In this video, we take an in-depth look at the recently FDA-approved antipsychotic, KarXT, also known by its brand name Cobenfy. This new drug represents a major breakthrough in schizophrenia treatment because, unlike traditional antipsychotics, it doesn’t rely on blocking dopamine receptors. Instead, KarXT works through a muscarinic agonist mechanism, making it a completely different approach to managing schizophrenia and other psychotic disorders.

We'll start by explaining the science behind KarXT and how its combination of Xanomeline and Trospium works together to provide effective symptom control while reducing many of the typical side effects seen in older medications. The benefits of KarXT go beyond just managing symptoms—its novel mechanism means patients may experience fewer issues like weight gain, fatigue, and extrapyramidal symptoms that are common with older antipsychotics. We’ll discuss what this Cobenfy approval means for patients and the potential impact it could have on psychiatric care moving forward. We’ll also cover the side effects of KarXT, including both the cholinergic and anticholinergic effects that you might expect from this type of medication.

While KarXT may offer fewer of the traditional side effects, it does come with its own considerations, such as dry mouth, constipation, and nausea. Plus, we’ll look into how Cobenfy compares to traditional dopamine-blocking antipsychotics and what clinicians should keep in mind when prescribing it. This video also touches on why the KarXT efficacy trials have generated so much excitement in the psychiatric community. The EMERGENT trials, which tested KarXT for schizophrenia, showed promising results with fewer discontinuations due to side effects compared to placebo. We’ll explain what these results mean and why Cobenfy for schizophrenia treatment could be a major advancement in the field of psychopharmacology.

If you’re interested in the future of mental health treatment or if you’re a healthcare professional looking to stay updated on the latest developments, this video will give you a thorough overview of KarXT, its unique approach, and how it stands out from other antipsychotics on the market. We’ll also share our thoughts on what this Cobenfy approval means for patients and whether KarXT could be the future of antipsychotic medication. By the end of this video, you’ll have a clear understanding of the benefits of KarXT, how it works, what to watch for in terms of KarXT side effects, and why this drug is considered a significant breakthrough in schizophrenia treatment.

Related:

  • A Closer Look at Alpha-2 Agonists for ADHD
  • The Evidence Base for Polypharmacy in ADHD
  • Guanfacine ER for Adults With ADHD?
  • Atomoxetine: Myths and Truths
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB7e_Print_App_Access.png

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

    The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.